By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PHARNEXT 

Pepiniere Sante Cochin
29 rue du Faubourg Saint Jacques
Paris    75014  France
Phone: 01-55-426200 Fax: 01-55-426201


SEARCH JOBS








Company News
Ipsen (IPN.PA) Joins PHARNEXT's Board Of Directors 6/30/2014 9:23:00 AM
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014 6:17:34 AM
PHARNEXT Raises an Additional €8 Million for Its PleotherapyTM Platform Applied to the Treatment of Charcot-Marie Tooth Disease and Alzheimer's Disease 2/9/2012 6:50:15 AM
PHARNEXT Has Completed Patient Recruitment for Its Phase II Clinical Trial of PXT3003 (the Company's First Pleodrug™) in Charcot-Marie-Tooth Disease 11/22/2011 10:42:23 AM
PHARNEXT Announces a €2.5 Million Round of Financing 9/8/2011 6:48:38 AM
PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the First Drug Generated by Its Pleotherapy(TM) Technology 12/3/2010 8:50:25 AM
OSEO Awards a €10.4 Million Funding Package to PHARNEXT, BioSystems International, Bordeaux Hospital (CMRR1), University Bordeaux Segalen and INSERM 11/18/2010 2:09:43 PM
PHARNEXT Raises Eur 4.8 Million Series A Funding 6/9/2010 6:57:32 AM
Ipsen and PHARNEXT Conclude an Exclusive Research, Development and Marketing Agreement 6/15/2009 10:03:31 AM
//-->